Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor Inc
(NQ:
XNCR
)
20.45
-0.39 (-1.87%)
Streaming Delayed Price
Updated: 9:45 AM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xencor Inc
< Previous
1
2
3
Next >
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
October 01, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2021 Financial Results
August 04, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
August 02, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
July 28, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021
From
Xencor, Inc.
Via
Business Wire
Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19
May 26, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
May 25, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
May 12, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2021 Financial Results
May 05, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases
April 28, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
April 28, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
April 10, 2021
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.